Neurosense Therapeutics is trading 8.39% higher at $1.55 in pre-market on November 3; no clear catalyst for the rebound was identified.
- The stock closed at $1.43 on November 2.
- Recent company news included a delay to the planned Health Canada filing for PrimeC, from December 2026 to March 2027, and an analyst downgrade amid Nasdaq listing concerns. These developments do not explain the pre-market move.